Skip to main content
SpringerLink
Log in

Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Circulating CA 15-3 antigen levels were evaluated in patients with benign diseases and breast cancer patients with no clinical evidence of disease after surgery (NED). Patients with breast cancer NED were followed for tumor recurrence or death during a median of 12.9 months (range 1 to 25 months). CA 15-3 and carcinoembryonic antigen (CEA) were compared in the same breast cancer NED patient population. Elevated CA 15-3 levels (>40 U/ml) were observed in 38 of 1220 patients with benign diseases (3.1%) and in 25 of 350 breast cancer NED patients (7.1%). Elevations of CEA (>5ng/ml) were observed in 23 patients with breast cancer NED (6.5%). Benign diseases that produced significant elevations of CA 15-3 were chronic hepatitis (42.9%), liver cirrhosis (13.3%), sarcoidosis (16.7%), tuberculosis (9.7%), and systemic lupus erythematosous (6.7%).

In breast cancer NED, initial elevations of CA 15-3 were observed in 12 of the 297 patients that remained free of disease during the follow-up, and in 13 of the 40 patients that relapsed (4.0% vs. 32.5%, p<0.001). Initial CEA levels were elevated in 16 patients that remained NED and in 7 patients that relapsed (5.3% vs. 17.5%, p<0.001). Serial determinations of CA 15-3 in patients continuously NED showed persistent elevations in 4 cases. Three of these exhibited concomitant benign diseases. In relapsing patients, serial tumor marker determinations showed that elevations of CA 15-3 before any other clinical evidence of recurrence occurred significantly more frequently than elevations of CEA (45% vs. 25%, p<0.001). Overall, two or more serial elevated values of CA 15-3 were observed in 7 cases, and 6 of them (85%) eventually relapsed. Median survival from study entry was 18.3 months in patients with breast cancer NED that had initial elevated CA 15-3, compared to 25+ months in those with negative CA 15-3 (p<0.0001).

We conclude that circulating levels of CA 15-3 antigen can be elevated in some patients with nonmalignant diseases, and that serial determinations of CA 15-3 may be useful in the postsurgical follow-up of patients with breast cancer when specific types of benign diseases that may cause elevations of the antigen are excluded. Additionally, CA 15-3 is more sensitive than CEA in the early diagnosis of breast cancer recurrences, and the simultaneous assay of CEA does not add information to that of CA 15-3 alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tobias R, Rothwell C, Wagner J, Green A, Liu Y-SV: Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 (abstract). Clin Chem 31: 986, 1985

    Google Scholar 

  2. Hayes DF, Zurawski VR, Kufe DW: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4: 1542–1550, 1986

    PubMed  Google Scholar 

  3. Colomer R, Lianes P, Ruibal A, Cortes-Funes H, Salvador L, Hornedo J: Circulating CA 15-3 levels in patients with breast cancer predict relapse and correlate with metastatic tumor burden (abstract). Proceedings Am Soc Clin Oncol 7: 20, 1988

    Google Scholar 

  4. Jäger W, Wildt L, Leyendecker G: CA 15/3 and CEA serum concentrations in breast cancer patients. In: Greten H, Klapdor R (eds.) Clinical Relevance of New Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1986, pp 167–173

    Google Scholar 

  5. Paulick R, Caffier H, Kaesemann H: Erste erfahrungen mit dem monoklonalen markersystem CA 15-3 bei mammakarzinompatientinnen. Tumor Diagn Ther 7: 85–87, 1986

    Google Scholar 

  6. Pons-Anicet DMF, Krebs BP, Mira R, Namer M: Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer 55: 567–569, 1987

    PubMed  Google Scholar 

  7. Yoshimoto M, Akiyama F, Watanabe S, Kasumi F, Fukami A, Nakajima T, Nishi M, Kajitani T, Takahashi S: Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer. Gan To Kagayu Ryoho 14: 2310–2315, 1987

    Google Scholar 

  8. Paladini G, Capelli M, Rivelli D, Plate L, Carmentano P, Bianchi D: CA 15-3 e carcinoma della mammella: considerazioni preliminari (abstract). Proceedings XI Congr Nazionale di Oncologia 1985; 342

  9. Sturm G, Schmidt-Rhode P, Schulz K-D, Frick M, Schulz U: The diagnostic value of the CA 15-3 determination in the post-care of breast cancer patients: first results of a prospective study. In: Klapdor R (ed) New Tumor Markers and their Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1987, pp 70–73

    Google Scholar 

  10. Tommasi M, Fantappie B, Distante V, Cataliotti L, Neri B, Ciatto S, Pacini P: The role of a new monoclonal antibody assay in the detection of recurrent breast cancer. Int J Biol Markers 1: 81–84, 1986

    PubMed  Google Scholar 

  11. Ruibal A, Genolla J, Rosell M, Moragas M: El CA 15-3-ELSA serio en patologias no tumorales (letter). Med Clin (Barc) 88: 476, 1987

    Google Scholar 

  12. Sacks NMP, Stacker SA, Thompson CH, Collins JP, Russell IS, Sullivan JA, McKenzie IFC: Comparison of mammary serum antigen (MSA) and CA 15-3 levels in the serum of patients with breast cancer. Br J Cancer 56: 820–824, 1987

    PubMed  Google Scholar 

  13. Stieber P, Diergarten K, Eiermann W, Albiez M, Fateh-Moghadam A: CA 15-3: evaluation and clinical value in breast carcinomas compared with CEA and TPA. In: Klapdor R (ed) New Tumor Markers and their Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1987, pp 46–51

    Google Scholar 

  14. Hilkens J, Buijs F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, van de Valk M: Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34: 197–206, 1984

    PubMed  Google Scholar 

  15. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223–232, 1984

    PubMed  Google Scholar 

  16. Ochi Y, Okabe H, Imokawa M: Antigen detection by the monoclonal antibodies CA 19-9, CA 125, and CA 15-3 in serum and body fluid of cancer and non-cancerous state. In: Klapdor R (ed) New Tumor Markers and their Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1987, pp 97–104

    Google Scholar 

  17. Gion M, Mione R, Dittadi R, Zari C, Bruscagnin G: CA 15-3 in breast cancer tissue. In: Klapdor R (ed) New Tumor Markers and Their Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1987, pp 342–347

    Google Scholar 

  18. Vendely P, Pandian MR: Correlation of a mammary tumor associated antigen (CA 15-3) with steroid receptors in human mammary tumor extracts (abstract). Clin Chem 32: 1126, 1986

    Google Scholar 

  19. Schenken LL, Pugh RP, Schmidt DM, Grden MA, Zidar BL: Antigen expression and steroid receptor status within human breast tumors (abstract). Proc Am Assoc Cancer Res 28: 180, 1987

    Google Scholar 

  20. Colomer R, Ruibal A, Genollá J, Salvador L: Circulating CA 15-3 antigen levels in patients with non-mammary malignancies. Br J Cancer 59, 1989 (in press)

  21. Breitbach GP, Kaul S, Behnken LJ, Wieser N, Altholz H, Bastert G: Tumour marker concentration in blood sera of patients with extended breast cancer in relation to metastatic localisation and tumour mass. In: Klapdor R (ed) New Tumor Markers and their Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1987, pp 57–57

    Google Scholar 

  22. Ingersleben G, Souchon R, Brand U, Fitzner R: CA 15-3 in comparison with CEA in the follow-up and therapy control of breast carcinoma: new aspects. In: Klapdor R (ed) New Tumor Markers and their Monoclonal Antibodies. Georg Thieme Verlag, Stuttgart, 1987, pp 113–117

    Google Scholar 

Download references

Author information

Author notes

  1. Ramón Colomer

    Present address: Division of Medical Oncology, Vincent T. Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, 20007, Washington D.C., USA

Authors and Affiliations

  1. Medical Oncology, Valle de Hebrón Hospital, 08035, Barcelona, Spain

    Ramón Colomer, Diego Rubio & Jose M. Del Campo

  2. Tumor Markers, Valle de Hebrón Hospital, 08035, Barcelona, Spain

    Alvaro Ruibal & José Genollá

  3. Radiation Therapy Units, Valle de Hebrón Hospital, 08035, Barcelona, Spain

    Ramon Bodi & Luis Salvador

  4. Tumor Markers Unit, Hospital General de Asturias, 33006, Oviedo, Asturias, Spain

    Alvaro Ruibal

Authors
  1. Ramón Colomer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alvaro Ruibal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Genollá
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Diego Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jose M. Del Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ramon Bodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luis Salvador
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colomer, R., Ruibal, A., Genollá, J. et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Tr 13, 123–133 (1989). https://doi.org/10.1007/BF01806524

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806524

Key words

Search

Navigation